Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aripiprazole 15, placebo Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

NCT00194077
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
4 Years to 9 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2015 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

NCT06372210
View directory record Official record
Conditions
Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions
Placebo IEM tablet, Abilify MyCite®, D-Tect Patch
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania

NCT00261443
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium or Valproate with placebo (PBO), Lithium or Valproate with Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
29
States / cities
Tuscaloosa, Alabama • Anaheim, California • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Study of Aripiprazole in Patients With Acute Bipolar Mania

NCT00097266
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Placebo, Aripiprazole, Haloperidol
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

NCT01149655
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Downy, California • Glendale, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

NCT01338298
View directory record Official record
Conditions
Hyperprolactinemia
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 2Phase 3 Interventional

Aripiprazole and Topiramate on Free-Choice Alcohol Use

NCT00884884
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Double Placebo, Aripiprazole 15, placebo, Aripiprazole 7.5, Placebo, Topiramate 100, Placebo, Topiramate 200, Placebo, Topiramate 100, Aripiprazole 15, Topiramate 100, Aripiprazole 7.5, Topiramate 100, Aripiprazole 15mg, Topiramate 200, Aripiprazole 7.5mg, Topiramate 200, Aripiprazole 15
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia

NCT00580125
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-00217830, Placebo, Aripiprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Garden Grove, California • Torrance, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole Effects on Alcohol Drinking and Craving

NCT01292057
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 40 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Aripiprazole on Cocaine Craving and Self-Administration

NCT00373880
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Aripiprazole + Cocaine, Placebo + Cocaine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

NCT00332241
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Boca Raton, Florida • Atlanta, Georgia • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

NCT01227668
View directory record Official record
Conditions
Irritability Associated With Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years to 17 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Dothan, Alabama • Phoenix, Arizona • Costa Mesa, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Adolescents With Schizophrenia

NCT00102063
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole tablet, 10 mg, Aripiprazole tablet, 30 mg, Placebo tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

NCT00198107
View directory record Official record
Conditions
Autistic Disorder
Interventions
Aripiprazole, Placebo, D-cycloserine
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

NCT00337571
View directory record Official record
Conditions
Behavioral Symptoms, Autistic Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
31
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Results available

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01490086
View directory record Official record
Conditions
Acute Schizophrenia, Schizoaffective Disorder
Interventions
RP5063, placebo, aripiprazole
Drug
Lead sponsor
Reviva Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 4 Interventional

Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

NCT00325689
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Quetiapine or Risperidone + Aripiprazole, Quetiapine or Risperidone + placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Aripiprazole Augmentation of Antidepressants in PTSD

NCT00489866
View directory record Official record
Conditions
PTSD
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

NCT00365859
View directory record Official record
Conditions
Autistic Disorder, Behavioral Symptoms
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
55
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia

NCT00345033
View directory record Official record
Conditions
Schizophrenia, Insulin Resistance
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2014 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

NCT03198078
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole (OPC-34712), Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole in Children and Adolescents With Bipolar I Disorder

NCT00110461
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
53
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 27, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

NCT02918370
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Abuse
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 27, 2026, 4:50 AM EDT